BRPI0821682A2 - Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. - Google Patents

Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.

Info

Publication number: BRPI0821682A2
Authority: BR; Brazil
Prior art keywords: antigen; monoclonal antibody; binding portion; isolated; vector
Prior art date: 2008-01-04

Application number

BRPI0821682-7A

Other languages

English (en)

Inventor

Randolf Kerschbaumer

Friedrich Scheiflinger

Manfred Rieger

Michael Thiele

C Geert Mudde

Juergen Muellberg

Rene Hoet

Original Assignee

Baxter Int

Baxter Healthcare Sa

Dyax Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-04

Filing date

2008-12-30

Publication date

2015-06-16

2008-12-30 Application filed by Baxter Int, Baxter Healthcare Sa, Dyax Corp filed Critical Baxter Int

2015-06-16 Publication of BRPI0821682A2 publication Critical patent/BRPI0821682A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)

BRPI0821682-7A 2008-01-04 2008-12-30 Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. BRPI0821682A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1898808P	2008-01-04	2008-01-04
US9468508P	2008-09-05	2008-09-05
PCT/EP2008/011146 WO2009086920A1 (en)	2008-01-04	2008-12-30	Anti mif antibodies

Publications (1)

Publication Number	Publication Date
BRPI0821682A2 true BRPI0821682A2 (pt)	2015-06-16

Family

ID=40535633

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0821682-7A BRPI0821682A2 (pt)	2008-01-04	2008-12-30	Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.

Country Status (22)

Country	Link
US (3)	US20090220521A1 (pt)
EP (4)	EP2548890A1 (pt)
JP (1)	JP5502752B2 (pt)
KR (2)	KR101654678B1 (pt)
CN (2)	CN103724430B (pt)
AU (1)	AU2008346517B2 (pt)
BR (1)	BRPI0821682A2 (pt)
CA (1)	CA2711029A1 (pt)
CY (1)	CY1117302T1 (pt)
DK (1)	DK2231707T3 (pt)
ES (3)	ES2623653T3 (pt)
HR (1)	HRP20150224T1 (pt)
IL (1)	IL206715A (pt)
MX (1)	MX2010007406A (pt)
NZ (3)	NZ611117A (pt)
PL (2)	PL2231707T3 (pt)
PT (1)	PT2231707E (pt)
RS (1)	RS53906B1 (pt)
RU (2)	RU2509777C2 (pt)
SI (1)	SI2231707T1 (pt)
WO (1)	WO2009086920A1 (pt)
ZA (1)	ZA201004973B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009086920A1 (en) *	2008-01-04	2009-07-16	Baxter International Inc.	Anti mif antibodies
JP2014526886A (ja) *	2011-07-15	2014-10-09	モルフォシス・アー・ゲー	マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
AU2012320597C1 (en)	2011-10-07	2015-10-15	Baxalta GmbH	oxMIF as a diagnostic marker
US9465037B2 (en)	2011-10-07	2016-10-11	Baxalta Incorporated	Characterization of CHO-MIF gene and protein, and use thereof
AU2013202693B2 (en)	2012-04-16	2015-01-22	Baxalta GmbH	Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
AU2013203957B9 (en) *	2012-04-16	2015-10-15	Baxalta GmbH	Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
CA2878494A1 (en)	2012-07-10	2014-01-16	Baxter Healthcare S.A.	Anti-mif immunohistochemistry
SG11201504392XA (en)	2012-12-07	2015-07-30	Baxter Int	Anti-mif antibody cell migration assay
EP3090262B1 (en) *	2014-01-03	2018-08-01	Baxalta GmbH	Anti-mif immunohistochemistry
EP3183581A1 (en)	2014-08-22	2017-06-28	Baxalta GmbH	Detection of cho-mif contaminations
WO2016156489A1 (en)	2015-03-31	2016-10-06	Baxalta GmbH	Dosage regimen for anti-mif antibodies
US20180155419A1 (en)	2015-05-18	2018-06-07	Baxalta GmbH	Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
US11098113B2 (en)	2016-09-15	2021-08-24	Vib Vzw	Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN109868311B (zh) *	2017-12-01	2023-10-20	上海市精神卫生中心	Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用
CA3098415A1 (en) *	2018-06-07	2019-12-12	Oncoone Research & Development Gmbh	Anti-oxmif/anti-cd3 antibody for cancer treatment
EP3757252B1 (en)	2019-06-28	2022-03-30	Walter Ag	A coated cutting tool
JP2023504620A (ja)	2019-12-06	2023-02-06	オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
KR20230079390A (ko)	2020-10-02	2023-06-07	온코원 리서치 앤드 디벨롭먼트 게엠베하	감소된 응집 능력 및 감소된 소수성을 갖는 개선된 항-oxMlF 항체
EP4288118A1 (en) *	2021-02-03	2023-12-13	OncoOne Research & Development GmbH	Anti-oxmif radioimmunoconjugate
EP4396227B1 (en)	2021-09-03	2025-07-09	OncoOne Research & Development GmbH	Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
WO2023133360A2 (en) *	2022-01-10	2023-07-13	Phenomic Ai	Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same
CN114573693A (zh) *	2022-04-25	2022-06-03	中国人民解放军陆军军医大学	一种听觉发育中免疫调节分子mif抗体制备方法
CN115814069B (zh) *	2022-10-31	2023-07-21	四川大学华西医院	Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途
AU2024233139A1 (en)	2023-03-03	2025-08-28	Oncoone Research & Development Gmbh	Improved bispecific anti-tumor antigen/anti-hsg antibodies for pre-targeting of hyperproliferative disorders
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025171411A1 (en) *	2024-02-09	2025-08-14	Herophilus, Inc.	Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080407A (en) *	1993-05-17	2000-06-27	The Picower Institute For Medical Research	Diagnostic assays for MIF
US6774227B1 (en) *	1993-05-17	2004-08-10	Cytokine Pharmasciences, Inc.	Therapeutic uses of factors which inhibit or neutralize MIF activity
JPH0977799A (ja) *	1995-09-13	1997-03-25	Sapporo Immuno Diagnostic Lab:Kk	ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
EP1156823B1 (en) *	1999-02-12	2008-10-29	The Scripps Research Institute	Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
AU2001238677A1 (en) *	2000-02-28	2001-09-12	Idec Pharmaceuticals Corporation	Method for preparing anti-mif antibodies
AR045563A1 (es) *	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
CN100457895C (zh) *	2006-05-24	2009-02-04	中国科学院生物物理研究所	鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
WO2009086920A1 (en) *	2008-01-04	2009-07-16	Baxter International Inc.	Anti mif antibodies

2008
- 2008-12-30 WO PCT/EP2008/011146 patent/WO2009086920A1/en not_active Ceased
- 2008-12-30 BR BRPI0821682-7A patent/BRPI0821682A2/pt not_active IP Right Cessation
- 2008-12-30 MX MX2010007406A patent/MX2010007406A/es active IP Right Grant
- 2008-12-30 PT PT08869976T patent/PT2231707E/pt unknown
- 2008-12-30 US US12/346,309 patent/US20090220521A1/en not_active Abandoned
- 2008-12-30 KR KR1020107017306A patent/KR101654678B1/ko active Active
- 2008-12-30 RS RS20150197A patent/RS53906B1/sr unknown
- 2008-12-30 EP EP20120189220 patent/EP2548890A1/en not_active Withdrawn
- 2008-12-30 EP EP16183733.1A patent/EP3118223B8/en active Active
- 2008-12-30 NZ NZ611117A patent/NZ611117A/en not_active IP Right Cessation
- 2008-12-30 ES ES14163839.5T patent/ES2623653T3/es active Active
- 2008-12-30 EP EP14163839.5A patent/EP2754671B1/en active Active
- 2008-12-30 RU RU2010132647/10A patent/RU2509777C2/ru active
- 2008-12-30 CN CN201410037650.3A patent/CN103724430B/zh not_active Expired - Fee Related
- 2008-12-30 SI SI200831400T patent/SI2231707T1/sl unknown
- 2008-12-30 NZ NZ586600A patent/NZ586600A/en not_active IP Right Cessation
- 2008-12-30 ES ES08869976.4T patent/ES2531629T3/es active Active
- 2008-12-30 HR HRP20150224TT patent/HRP20150224T1/hr unknown
- 2008-12-30 JP JP2010541032A patent/JP5502752B2/ja not_active Expired - Fee Related
- 2008-12-30 DK DK08869976.4T patent/DK2231707T3/en active
- 2008-12-30 KR KR1020167023984A patent/KR20160105943A/ko not_active Ceased
- 2008-12-30 PL PL08869976T patent/PL2231707T3/pl unknown
- 2008-12-30 PL PL16183733T patent/PL3118223T3/pl unknown
- 2008-12-30 CN CN200880127872.7A patent/CN101983207B/zh not_active Expired - Fee Related
- 2008-12-30 ES ES16183733T patent/ES2791333T3/es active Active
- 2008-12-30 CA CA2711029A patent/CA2711029A1/en not_active Abandoned
- 2008-12-30 NZ NZ596409A patent/NZ596409A/xx not_active IP Right Cessation
- 2008-12-30 EP EP08869976.4A patent/EP2231707B1/en active Active
- 2008-12-30 AU AU2008346517A patent/AU2008346517B2/en not_active Ceased
2010
- 2010-04-26 US US12/767,635 patent/US8668909B2/en not_active Expired - Fee Related
- 2010-06-30 IL IL206715A patent/IL206715A/en active IP Right Grant
- 2010-07-14 ZA ZA2010/04973A patent/ZA201004973B/en unknown
2013
- 2013-12-03 RU RU2013153592/10A patent/RU2013153592A/ru not_active Application Discontinuation
2014
- 2014-01-17 US US14/157,967 patent/US20150023978A1/en not_active Abandoned
2015
- 2015-03-13 CY CY20151100250T patent/CY1117302T1/el unknown

Also Published As

Publication number	Publication date
AU2008346517B2 (en)	2013-12-05
KR20160105943A (ko)	2016-09-07
NZ586600A (en)	2012-05-25
NZ611117A (en)	2014-10-31
WO2009086920A1 (en)	2009-07-16
ES2531629T3 (es)	2015-03-18
JP2011510616A (ja)	2011-04-07
ES2791333T3 (es)	2020-11-03
CN101983207B (zh)	2016-01-20
JP5502752B2 (ja)	2014-05-28
EP3118223B1 (en)	2020-02-19
US20150023978A1 (en)	2015-01-22
HK1147762A1 (en)	2011-08-19
EP3118223A1 (en)	2017-01-18
ZA201004973B (en)	2011-03-30
NZ596409A (en)	2013-05-31
US20100260768A1 (en)	2010-10-14
KR101654678B1 (ko)	2016-09-08
RU2509777C2 (ru)	2014-03-20
EP2754671A3 (en)	2015-07-08
PT2231707E (pt)	2015-03-25
RU2010132647A (ru)	2012-02-10
CN103724430A (zh)	2014-04-16
EP2754671A2 (en)	2014-07-16
CN101983207A (zh)	2011-03-02
SI2231707T1 (sl)	2015-04-30
EP2231707B1 (en)	2014-12-24
KR20100102197A (ko)	2010-09-20
AU2008346517A1 (en)	2009-07-16
CA2711029A1 (en)	2009-07-16
EP2548890A1 (en)	2013-01-23
CN103724430B (zh)	2016-09-21
PL3118223T3 (pl)	2021-04-06
US20090220521A1 (en)	2009-09-03
HRP20150224T1 (xx)	2015-06-05
IL206715A (en)	2015-06-30
US8668909B2 (en)	2014-03-11
EP3118223B8 (en)	2020-04-15
RU2013153592A (ru)	2015-06-10
EP2231707A1 (en)	2010-09-29
MX2010007406A (es)	2010-10-05
EP2754671B1 (en)	2016-12-21
ES2623653T3 (es)	2017-07-11
RS53906B1 (sr)	2015-08-31
PL2231707T3 (pl)	2015-05-29
IL206715A0 (en)	2010-12-30
CY1117302T1 (el)	2017-04-26
DK2231707T3 (en)	2015-03-02

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B25A	Requested transfer of rights approved	Owner name: BAXTER HEALTHCARE S.A. (CH) , DYAX CORPORATION (US
2018-05-22	B25A	Requested transfer of rights approved	Owner name: DYAX CORPORATION (US) , BAXALTA INCORPORATED (US)
2018-10-30	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-03-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BR112014000263A2 (pt)	2017-02-14	anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
BRPI0905761A2 (pt)	2015-07-14	Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BRPI0907735A2 (pt)	2017-06-13	anticorpo, ácido nucleico isolado, célula hospedeira, camundongo transgênico, hibridoma, composição farmacêutica, método para tratar uma condição ou uma doença associada a um distúrbio imune, cristal, proteína de fusão, e, método para preparar o anticorpo
BRPI0819211A2 (pt)	2015-06-16	Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
BRPI0813242A2 (pt)	2015-08-18	Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
UA105009C2 (uk)	2014-04-10	Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
BRPI0905076A2 (pt)	2015-07-07	Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BR112012003064B8 (pt)	2021-05-25	anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
BR112012007365A2 (pt)	2016-11-22	proteínas de ligação à il-1
JO3812B1 (ar)	2021-01-31	أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
WO2013078455A3 (en)	2013-10-31	Proteomic identification of antibodies
BRPI0810211A2 (pt)	2014-10-21	Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
LT3421498T (lt)	2022-03-10	Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
CL2007003479A1 (es)	2009-01-23	Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
CN103562403A8 (zh)	2018-01-26	识别肿瘤起始细胞的抗体和抗原及其应用
BRPI0916945A2 (pt)	2015-11-24	métodos para tratar uma doença auto-imune ou distúrbio inflamatório em um indivíduo humano, para tratar esclerose múltipla em um indivíduo, e para identificar anticorpos, anticorpo humano, humanizado ou quimérico isolado ou um fragmento de ligação de antígeno do mesmo, e, proteína de ligação isolada.
BR112015014751A2 (pt)	2017-10-10	anticorpos anti-tau humanos
BR112012018914A2 (pt)	2017-07-25	"anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
AR075882A1 (es)	2011-05-04	Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
BRPI0713000A8 (pt)	2017-12-05	Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
CY1116306T1 (el)	2017-02-08	Συλλογες γενετικων πακετων που αποτελουνται απο νεα hc cdr1, cdr2, και cdr3 και νεα lc cdr1, cdr2 cdr3 σχεδια
BRPI0819688A2 (pt)	2015-06-16	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
WO2017193094A8 (en)	2018-06-07	Dna monoclonal antibodies targeting checkpoint molecules